This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Blau Farmacêutica, Bergamo tell Brazil CADE merger won't affect supply of chemotherapy drugs

By Paula Mariane ( March 21, 2023, 20:34 GMT | Insight) -- Brazil-based pharmaceutical company Blau Farmacêutica has told the national competition authority that its planned acquisition of rival Bergamo won’t affect the market supply of chemotherapy drugs cisplatin and carboplatin. The parties also told the Administrative Council for Economic Defense, or CADE, that there are "strong and established competitors" in these markets, and that they can meet potential additional demand from the parties' customers. Brazil-based pharmaceutical company Blau Farmacêutica has told the national competition authority that its planned acquisition of rival Bergamo won’t affect the market supply of chemotherapy drugs cisplatin and carboplatin....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login